High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type i interferon signature is a risk factor for the development of autoimmune congenital heart block

Annals of the Rheumatic Diseases

Volumn 76, Issue 8, 2017, Pages 1476-1480

  Lisney, Anna R ^a,b   Szelinski, Franziska ^a   Reiter, Karin ^a   Burmester, Gerd R ^a   Rose, Thomas ^a,b   Dörner, Thomas ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

congenital heart block; interferon ; neonatal lupus syndrome; sialoadhesin; SIGLEC1

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; DEXAMETHASONE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INTERFERON; LA ANTIBODY; RO ANTIBODY; SIALOADHESIN; TYPE I INTERFERON; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; SIGLEC1 PROTEIN, HUMAN; SS-A ANTIBODIES; SS-B ANTIBODIES;

ADULT; ARTICLE; AUTOIMMUNE CONGENITAL HEART BLOCK; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS; FLOW CYTOMETRY; HEART BLOCK; HUMAN; MONOCYTE; PATHOGENESIS; PLACENTAL TRANSFER; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCYTOSIS; AUTOIMMUNE DISEASES; CASE CONTROL STUDY; FETOMATERNAL TRANSFUSION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; SJOGREN'S SYNDROME;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HEART BLOCK; HUMANS; HYDROXYCHLOROQUINE; INFANT, NEWBORN; INTERFERON TYPE I; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MATERNAL-FETAL EXCHANGE; MONOCYTES; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; SIALIC ACID BINDING IG-LIKE LECTIN 1; SJOGREN'S SYNDROME; TRANSCYTOSIS;

EID: 85024382840     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210927     Document Type: Article

References (20)

1. Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015;11:301-12.
2. Chameides L, Truex RC, Vetter V, et al. Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med 1977;297:1204-7.
3. Clancy RM, Kapur RP, Molad Y, et al. Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 2004;50:173-82.
4. López de Padilla CM, Niewold TB. The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases. Gene 2016;576(1 Pt 1):14-21.
5. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjögren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024-33.
6. Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum 2008;58:1136-45.
7. Rose T, Grötzkau A, Hirseland H, et al. Ifn and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 2013;72:1639-45.
8. R ose T, Szelinski F, Lisney A, et al. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. RMD Open 2016;2:e000292.
9. Brucato A, Jonzon A, Friedman D, et al. Proposal for a new definition of congenital complete atrioventricular block. Lupus 2003;12:427-35.
10. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
11. Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12. Evans AT, Carandang G, Quilligan EJ, et al. Interferon responses in maternal and fetal mice. Am J Obstet Gynecol 1985;152:99-102.
13. Hedlund M, Thorlacius GE, Ivanchenko M, et al. Expression of IFN-Regulated Genes in autoantibody exposed babies in Utero [abstract]. Arthritis Rheum 2016;68(suppl 10).
14. Espinosa A, Zhou W, Ek M, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006;176:6277-85.
15. S trandberg L, Ambrosi A, Espinosa A, et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008;28:220-31.
16. O hlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J Immunol 2002;56:456-69.
17. I shikawa T, Takizawa T, Iwaki J, et al. Fc gamma receptor IIb participates in maternal IgG trafficking of human placental endothelial cells. Int J Mol Med 2015;35:1273-89.
18. Dörner T, Chaoui R, Feist E, et al. Significantly increased maternal and fetal IgG autoantibody levels to 52 kD Ro (SS-A) and La(SS-B) in complete congenital heart block. J Autoimmun 1995;8:675-84.
19. Lövgren T, Eloranta ML, Båve U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum 2004;50:1861-72.
20. Yazigi A, De Pecoulas AE, Vauloup-Fellous C, et al. Fetal and neonatal abnormalities due to congenital rubella syndrome: a review of literature. J Matern Fetal Neonatal Med 2017;30:274-78.